46brooklyn Research is an Ohio non-profit corporation whose purpose is to improve the accessibility and usability of U.S. drug pricing data. 46brooklyn takes the myriad drug pricing data sources scattered across the web and stitches them together into data visualizations that can be used by the public to better understand how the drug supply chain functions. 46brooklyn also writes and publishes original research that uses the data within its public data visualizations to shine light on the hidden and complex underbelly of the drug supply chain.
At 46brooklyn, we believe the rampant complexity that is characteristic of how our drugs are priced is creating serious consequences for payers, patients, and providers across this country. Our purpose is to unlock the value buried in our country’s vast but disparate drug pricing databases to bring awareness to the nature and design of this complexity. Our hope is that better awareness and education will help improve the accountability of our supply chain and, in time, lead to the much-needed simplification of how drugs are priced.
46brooklyn Research (EIN #83-3213092) is an Ohio non-profit corporation in the process of applying for 501(c)(3) status. You should contact your tax advisor with any questions you might have related to any contributions you make to 46brooklyn Research.
Two years working as President of a chain of community pharmacies was all the exposure Eric needed to know something was very wrong with our prescription drug supply chain. He left in July 2018 and formed 46brooklyn to find answers to his questions, and share his learnings along the way. Eric has 17 years of experience across a wide variety of technical and management roles on both "Wall Street" and "Main Street". He has worked within, invested in, or studied dozens of industries over his professional career - and this one is by far the biggest cluster. Eric graduated from University of Florida in 2001 with a BS in Chemical Engineering, and obtained an MBA from Harvard Business School in 2008.
Born and raised in pharmacy, Antonio has been crawling around pharmacies his entire life. After three years as a pharmacy technician and two years of pre-pharmacy curriculum, Antonio diverted course, graduating from The Ohio State University in 2007 with dual degrees in communications and political science before moving into the world of association management. Thinking that pharmacy would be in his rear-view mirror forever, he ended up making his way back to his pharmacy home, heading up government affairs for the Ohio Pharmacists Association, a trade organization with a strong track record of advocating for drug pricing transparency. After years of studying the pharmacy marketplace, Antonio became increasingly perplexed and concerned as he saw drug costs spiking while payouts to pharmacies were declining. Knowing something was being lost somewhere in the middle of an ever-growing transaction, Antonio has spent years working to crack the drug pricing code and pull the rug out from what he believes is one of the most dysfunctional marketplaces in the world.
All photos and creative design of this site by Benjamin Rivet of Journeyman Productions. Thank you Ben! Your creative work sets a high bar for us to match with our content! 🙏🙏🙏
We are constantly humbled by the insanely powerful data/analytics machine that is Tableau. How this product can do what it does is a mystery to us. Thankfully the folks over there figured it out because we couldn't imagine how we would do this work without it!
One of the most important tools we have for obtaining information is the invaluable work of journalists. The opaque prescription drug industry is in desperate need of scrutiny, and many of the best journalists in the world have been working to provide it. We regularly will link and reference their work, which at times might be buried behind a paywall. Please consider the value of their work by considering financial support of their vital efforts.
There are dozens of individuals who have helped educate us over the years on the complexities and inner-workings of the drug supply chain. While we are constantly learning, we owe tremendous thanks to those who have helped fill our knowledge gaps, and especially those who helped with the refining and launch of this project.